Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Retained Earnings (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Retained Earnings data on record, last reported at -$122.3 million in Q3 2025.

  • For Q3 2025, Retained Earnings fell 30.11% year-over-year to -$122.3 million; the TTM value through Sep 2025 reached -$122.3 million, down 30.11%, while the annual FY2024 figure was $5000.0, 141.67% up from the prior year.
  • Retained Earnings reached -$122.3 million in Q3 2025 per RANI's latest filing, down from -$116.9 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $5000.0 in Q4 2024 and bottomed at -$122.3 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$47.2 million, with a median of -$30.6 million recorded in 2022.
  • The widest YoY moves for Retained Earnings: up 141.67% in 2024, down 803620.0% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$3.1 million in 2021, then plummeted by 1138.67% to -$38.9 million in 2022, then soared by 99.97% to -$12000.0 in 2023, then surged by 141.67% to $5000.0 in 2024, then plummeted by 2446100.0% to -$122.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$122.3 million in Q3 2025, -$116.9 million in Q2 2025, and -$110.2 million in Q1 2025.